{'fraction_non_alphanumeric': 0.046789989118607184, 'fraction_numerical': 0.04026115342763874, 'mean_word_length': 4.935483870967742, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Bupropion‐SR in treatment of social phobia

A 12‐week, open label flexible dosing study was conducted to evaluate the efficacy of bupropion‐SR in the treatment of generalized social phobia. The primary outcome measures include the Clinical Global Impression of Improvement (CGI‐I) and the Brief Social Phobia Rating Scale (BSPS). A total of 18 subjects were enrolled. Five of the ten subjects who completed all 12 weeks were considered as responders. Response to treatment was defined as a CGI‐I score of 1 or 2, (“much improved” or “very much improved,” respectively) and a >50% decrease in BSPS score. The final doses for the completers ranged between 200 and 400 mg/day (mean 366±68 mg/day). The medication was generally well tolerated. Findings from this open‐label trial suggest that bupropion‐SR may be useful in treating generalized social phobia. Depression and Anxiety 12:111–113, 2000. © 2000 Wiley‐Liss, Inc.